This combination tablet contains Telmisartan, an angiotensin II receptor blocker (ARB), and Nebivolol, a third-generation beta-1 selective blocker with nitric oxide–mediated vasodilatory properties. Telmisartan works by blocking angiotensin II receptors, thereby relaxing blood vessels, reducing vascular resistance, and lowering blood pressure without affecting heart rate significantly. Nebivolol complements this action by reducing heart rate, decreasing myocardial oxygen demand, and promoting vasodilation through NO release, which enhances endothelial function. Together, they provide synergistic antihypertensive effects, offering both peripheral vasodilation and cardioprotection. This combination is particularly beneficial in patients with uncontrolled hypertension on monotherapy, those at high cardiovascular risk, or patients with coexisting conditions such as heart failure, diabetes, or metabolic syndrome. It provides effective 24-hour blood pressure control with once-daily dosing.
Common side effects include dizziness, headache, fatigue, and mild gastrointestinal disturbances. Nebivolol may cause bradycardia (slow heart rate), while Telmisartan can sometimes cause mild hyperkalemia (elevated potassium levels). Rare but serious adverse effects include severe hypotension, allergic reactions, kidney function impairment, and worsening of heart failure in susceptible individuals. Most side effects are dose-dependent and mild.
Telmisartan 40 mg + Nebivolol 5 mg Tablet is indicated for the management of essential hypertension in adults, particularly in patients who require combination therapy to achieve target blood pressure. It is also useful in patients with concomitant heart failure or left ventricular dysfunction as part of a comprehensive cardiovascular risk reduction plan.
This combination should be taken strictly under medical supervision. It is contraindicated in patients with severe bradycardia, advanced heart block, cardiogenic shock, or severe hepatic impairment. Caution is advised in patients with renal impairment, electrolyte disturbances, or heart failure. It is not recommended during pregnancy and breastfeeding, as ARBs can harm fetal development and beta-blockers can affect neonatal heart rate. Alcohol consumption should be minimized as it can potentiate the blood pressure–lowering effect. Dose should not be stopped abruptly, as sudden discontinuation may cause rebound hypertension or worsening of cardiac symptoms. Regular monitoring of blood pressure, heart rate, kidney function, and electrolytes is recommended during therapy.
Store the tablets in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep the medication in its original blister packaging and out of the reach of children. Do not use after the expiry date mentioned on the pack.